Suchergebnisse - "Shiu, Kai-Keen"

PubPharm (13)

1

Genetic and immune landscape evolution in MMR-deficient colorectal cancer

enthalten in: The Journal of pathology | 2024

von Challoner, B. | Woolston, A. | Lau, D. | +38

2

Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

enthalten in: Nature communications | 2023

von Hasan, A. | Cremaschi, P. | Wetterskog, D. | +121

3

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Adams, R. | Fisher, D. | Graham, J. | +19

CommentIn: J Clin Oncol. 2021 Nov 20;39(33):3656-3659. - PMID 34516761

4

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

enthalten in: Cancer cell | 2021

von Au, L. | Hatipoglu, E. | Robert de Massy, M. | +155

CommentIn: Cell Rep Med. 2021 Nov 16;2(11):100445. - PMID 34841292

5

Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade : Analysis of the KEYNOTE 177 Trial and Validation Cohorts

enthalten in: Gastroenterology | 2021

von Bortolomeazzi, M. | Keddar, M. | Montorsi, L. | +26

6

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177) : an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Andre, T. | Amonkar, M. | Norquist, J. | +17

7

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

enthalten in: The New England journal of medicine | 2020

von André, T. | Shiu, K. | Kim, T. | +119

CommentIn: N Engl J Med. 2020 Dec 3;383(23):2283-2285. - PMID 33264550

8

Representative Sequencing : Unbiased Sampling of Solid Tumor Tissue

enthalten in: Cell reports | 2020

von Litchfield, K. | Stanislaw, S. | Spain, L. | +130

9

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D) : a phase 2-3 randomised trial

enthalten in: The lancet. Gastroenterology & hepatology | 2018

von Adams, R. | Brown, E. | Brown, L. | +14

CommentIn: Lancet Gastroenterol Hepatol. 2018 Mar;3(3):143-145. - PMID 29254888

10

Functional characterization of the 19q12 amplicon in grade III breast cancers

enthalten in: Breast cancer research : BCR | 2012

von Natrajan, R. | Mackay, A. | Wilkerson, P. | +13